Which CGRP ligand-targeting monoclonal antibody is used for migraine prevention?

Prepare for the Pharmacology IV – Headache Therapeutics Test. Review the therapeutic approaches, tackle multiple-choice questions with explanations, and boost your test-taking confidence. Ace your exam with precision!

Multiple Choice

Which CGRP ligand-targeting monoclonal antibody is used for migraine prevention?

The main idea is that some CGRP therapies target the CGRP ligand itself, while others target the CGRP receptor or are small-molecule antagonists (gepants). Fremanezumab is a monoclonal antibody that binds the CGRP ligand, preventing it from activating its receptor. By neutralizing CGRP, it helps reduce the frequency of migraine attacks and is used for migraine prevention. Erenumab, in contrast, targets the CGRP receptor rather than the ligand. Zavegepant and Ubrogepant are gepants, small-molecule antagonists that also block the CGRP receptor rather than being antibodies against the ligand. Thus, among these options, fremanezumab is the ligand-targeting monoclonal antibody used for migraine prevention.

The main idea is that some CGRP therapies target the CGRP ligand itself, while others target the CGRP receptor or are small-molecule antagonists (gepants). Fremanezumab is a monoclonal antibody that binds the CGRP ligand, preventing it from activating its receptor. By neutralizing CGRP, it helps reduce the frequency of migraine attacks and is used for migraine prevention.

Erenumab, in contrast, targets the CGRP receptor rather than the ligand. Zavegepant and Ubrogepant are gepants, small-molecule antagonists that also block the CGRP receptor rather than being antibodies against the ligand.

Thus, among these options, fremanezumab is the ligand-targeting monoclonal antibody used for migraine prevention.

More practice questions